Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Bacterial Vaginosis Drugs Market - Segments and Forecast by Technavio

Technavio Research
Posted on: 03 Oct 17

The global bacterial vaginosis (BV) drugs marketis expected to grow at a CAGR of more than 2% during the forecast period, according to Technavio’s latest report.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170929005277/en/

Technavio has published a new report on the global bacterial vaginosis drugs market from 2017-2021. (Photo: Business Wire)

In this report, Technavio covers the market outlook and growth prospects of the global bacterial vaginosis drugs market for 2017-2021. The market is segmented based on ROA, which includes oral and topical and geography, which includes the Americas, EMEA, and APAC.

The global BV drugs market belongs to the wide spectrum of global infectious disease therapeutics market. The global infectious disease therapeutics market can be broadly divided into several sub-markets with the BV drugs market being one of them. The rising awareness about women’s health and wellness and advent of new drugs such as VivaGel BV is expected to foster the growth of the global BV drugs market.

Technavio’s healthcare and life sciencesresearch analysts categorize the global bacterial vaginosis drugs market into the following segments by regions:

  • Americas
  • EMEA
  • APAC

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Americas: largest bacterial vaginosis drugs market

The Americas dominated the global BV drugs market with a market share of almost 42% in 2016. The US was the largest revenue contributor, capturing a significant portion of the market. This is due to the high investment in the healthcare segment in the US. Apart from the US, Canada, Brazil, and Mexico are expected to be significant contributors in the BV drugs market.

“High prevalence rate of the indication in the female population of the region is expected to act as a driver for the BV drugs market in the region. BV is the most common type of vaginal infection affecting women aged between 15-44 years of age. BV is also highly prevalent in pregnant women. It is expected that around 15% of the pregnant women in the US suffer from BV,” says Sapna Jha, a lead analyst at Technavio for research on infectious and rare diseases.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Bacterial vaginosis drugs market in EMEA

The growing awareness regarding women's health and established healthcare infrastructure in Europe have led demand of BV drugs market in the region. The developed economies of Europe such as the UK, Italy, Spain, Germany, and France hold the major share of the market in the region.

“The growing product approvals are expected to fuel the market growth in EMEA. For instance, VivaGel BV by Starpharma Holdings received marketing approval in the European Union for rapid relief of BV in September 2015,” adds Sapna.

Bacterial vaginosis drugs market in APAC

APAC is one of the most attractive regions for the BV drugs market. This is majorly due to the rising healthcare expenditure by the developing economies such as India and China. Also, China is one of the fastest growing pharma markets and is expected to lead the BV drugs market in the region. The growth is attributed to the investment by the government in the healthcare sector.

However, providing adequate healthcare facilities to large population residing below the poverty line is a huge challenge for these countries. Also, low awareness rate regarding the women health is a huge constraint hindering the growth of the BV drugs market in the region.

The top vendors in the global bacterial vaginosis drugs market highlighted in the report are:

  • Bayer
  • Pfizer
  • Sanofi
  • Starpharma Holdings

Browse Related Reports:

-- Global Antibiotics Market 2017-2021

-- Global Antibiotics Market 2017-2021Global Animal Growth Enhancers Market 2017-2021

-- Global Antibiotics Market 2017-2021Global Animal Growth Enhancers Market 2017-2021Global Food Allergen Testing Market 2017-2021

-- Global Antibiotics Market 2017-2021 Global Animal Growth Enhancers Market 2017-2021 Global Food Allergen Testing Market 2017-2021About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170929005277/en/

Business Wire
www.businesswire.com

Last updated on: 03/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.